Novel Combination Using Next Generation HSV-1 Oncolytic Immunotherapy
Time: 2:00 pm
day: Day Two
Details:
• Development of the next generation oncolytic HSV-1 immunotherapy
• RP1 combined with nivolumab overcomes resistance in PD-1 failed melanoma
• RP1 monotherapy is safe and effective in solid organ transplant recipients
